SciClone Pharmaceuticals (Holdings) Limited
HKEX:6600.HK
18.72 (HKD) • At close June 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 1,809.191 | 1,671.829 | 2,127.488 | 1,118.986 | 919.49 | 275.962 | 481.629 |
| Short Term Investments
| 414.099 | 969.807 | 132.947 | 70.013 | 123.761 | 8.698 | 129.488 |
| Cash and Short Term Investments
| 2,223.29 | 2,641.636 | 2,260.435 | 1,188.999 | 1,043.251 | 284.66 | 611.117 |
| Net Receivables
| 867.954 | 816.806 | 562.287 | 547.553 | 387.66 | 622.272 | 385.594 |
| Inventory
| 308.285 | 140.56 | 174.66 | 171.585 | 140.199 | 145.401 | 143.795 |
| Other Current Assets
| 4.735 | 1.485 | 1.678 | 0.777 | 0.906 | 3.496 | 2.502 |
| Total Current Assets
| 3,447.107 | 3,600.487 | 2,999.06 | 1,908.914 | 1,572.016 | 1,055.829 | 1,143.008 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 39.421 | 28.625 | 29.878 | 14.264 | 35.103 | 52.437 | 47.777 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 396.039 | 542.241 | 606.095 | 652.691 | 169.251 | 143.468 | 127.067 |
| Goodwill and Intangible Assets
| 396.039 | 542.241 | 606.095 | 652.691 | 169.251 | 143.468 | 127.067 |
| Long Term Investments
| 110.637 | -826.706 | 288.026 | 218.275 | -61.299 | 26.458 | -106.83 |
| Tax Assets
| 0 | 0.651 | 1.52 | 13.336 | 0 | -26.458 | 106.83 |
| Other Non-Current Assets
| 7.046 | 975.108 | 138.103 | 75.164 | 130.752 | 44.543 | 109.799 |
| Total Non-Current Assets
| 553.143 | 719.919 | 1,063.622 | 973.73 | 273.807 | 240.448 | 284.643 |
| Total Assets
| 4,000.25 | 4,320.406 | 4,062.682 | 2,882.644 | 1,845.823 | 1,296.277 | 1,427.651 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 236.591 | 102.717 | 126.92 | 57.546 | 224.321 | 165.744 | 171.679 |
| Short Term Debt
| 13.064 | 430.59 | 393.933 | 789.39 | 19.466 | 22.206 | 19.14 |
| Tax Payables
| 62.08 | 42.09 | 25.035 | 84.283 | 62.812 | 42.364 | 253.738 |
| Deferred Revenue
| -13.064 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 461.653 | 358.125 | 435.917 | 540.835 | 62.812 | 42.364 | 253.738 |
| Total Current Liabilities
| 698.244 | 891.432 | 956.77 | 1,387.771 | 306.599 | 230.314 | 444.557 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 19.768 | 422.037 | 773.335 | 1,173.559 | 6.992 | 17.354 | 19.642 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 16.963 | 14.57 | 14.981 | 9.258 | 6.24 | 4.938 | 2.975 |
| Other Non-Current Liabilities
| 0.208 | 0.205 | 0.188 | 0.194 | 0.815 | 0.8 | 0.579 |
| Total Non-Current Liabilities
| 36.939 | 436.812 | 788.504 | 1,183.011 | 14.047 | 23.092 | 23.196 |
| Total Liabilities
| 735.183 | 1,328.244 | 1,745.274 | 2,570.782 | 320.646 | 253.406 | 467.753 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.216 | 0.237 | 0.232 | 0.192 | 0 | 0 | 0 |
| Retained Earnings
| 1,839.778 | 934.019 | 290.394 | 148.997 | 229.044 | -171.279 | -702.778 |
| Accumulated Other Comprehensive Income/Loss
| 410.564 | 314.458 | 273.918 | 147.098 | 1,288.146 | 0 | 0 |
| Other Total Stockholders Equity
| 1,014.509 | 1,743.448 | 1,752.864 | 15.575 | 7.987 | 1,214.15 | 1,662.676 |
| Total Shareholders Equity
| 3,265.067 | 2,992.162 | 2,317.408 | 311.862 | 1,525.177 | 1,042.871 | 959.898 |
| Total Equity
| 3,265.067 | 2,992.162 | 2,317.408 | 311.862 | 1,525.177 | 1,042.871 | 959.898 |
| Total Liabilities & Shareholders Equity
| 4,000.25 | 4,320.406 | 4,062.682 | 2,882.644 | 1,845.823 | 1,296.277 | 1,427.651 |